Adapting to Remote Trials
The trend of adaptive and remote trial design is here to stay as we move into 2021 and beyond. In order to capitalize on all the benefits these trials have to offer, clinical research sites should look to strategic deployment of the technology that empowers these trial types.
CTMS is the First Step to Successful Remote Clinical Trials
The FDA defines an adaptive design as “a clinical trial design that allows for prospectively planned modifications…based on accumulating data.” Beyond adaptive models, the Covid-19 pandemic has necessitated every site to develop a remote-model in order to complete their trial work. These trends will only exacerbate in the years to come. Adaptive and remote trials cannot be successfully executed without the backbone of CTMS and eClinical solutions that provide a site with the flexibility and data it needs to adjust a trial to patient needs and lead/lag findings in real-time. The ability to easily and effectively deploy remote trials elevates opportunities for research sites, priming them for increased sponsor awards and patient engagement. In order to capitalize on all the benefits these trials have to offer, clinical research sites must embrace the myriad of technologies that make remote trials possible including video, electronic consent, and remote workflow capabilities.
The pharmaceutical industry is expected to increase to $1.5 trillion by 2023; preparation for the next few years is critical for site success. Therefore, a clear focus on trends that will impact clinical trials will benefit any research leader and clinical site team. Discover how to prepare your site for the upcoming year – download our latest guide 2021 Trends That Will Impact Clinical Trials